Name | 6-ethoxy-2-benzothiazolesulfonamide |
Synonyms | L-643786 PNU-4191 ETHOXZOLAMIDE 6-ETHOXYZOLAMIDE 6-ethoxy-2-benzothiazolesulfonamid 6-ETHOXY-2-BENZOTHIAZOLESULFONAMIDE 6-ethoxy-2-benzothiazolesulfonamide 2-Benzothiazolesulfonamide, 6-ethoxy- 6-Ethoxy-1,3-benzothiazole-2-sulfonamide |
CAS | 452-35-7 |
EINECS | 207-199-5 |
InChI | InChI=1/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13) |
Molecular Formula | C9H10N2O3S2 |
Molar Mass | 258.32 |
Density | 1.4767 (rough estimate) |
Melting Point | 190-193°C(lit.) |
Boling Point | 464.9±37.0 °C(Predicted) |
Flash Point | 235°C |
Water Solubility | 10.33mg/L(25 ºC) |
Solubility | DMSO (Slightly), Ethyl Acetate (Slightly) |
Vapor Presure | 8.05E-09mmHg at 25°C |
Appearance | Solid |
Color | Off-White |
Merck | 13,3790 |
pKa | pKa 8.12(H2O t=25.0) (Uncertain) |
Storage Condition | Refrigerator |
Refractive Index | 1.6800 (estimate) |
In vitro study | Ethoxzolamide (ETZ) treatment causes >90% inhibition of reporter GFP fluorescence in infected macrophages. Moreover, in a 9-day macrophage survival assay, Ethoxzolamide (ETZ) treatment significantly inhibits the ability of M. tuberculosis to grow intracellularly. |
In vivo study | It is discovered that the lipid-soluble ethoxzolamide is converted in vivo to a water-soluble metabolite, while retaining high activity againstt the enzyme. At the minimal dose for maximal effect (4 mg/kg i.v. at 45 min) the IOP lowering is 4.2 mmHg, the concentration in anterior uvea is 2.5 pmol/kg, and the fractional inhibition of the enzyme (i) is 0.9995. The effect declines rapidly, attributable to the very short half-life of drug in plasma, leading to depletion of free drug in the anterior uvea and other tissues. Ethoxzolamide (ETZ) strongly downregulates GFP reporter fluorescence in mouse lungs, with 3-fold inhibition of GFP signal compare to that in the mock-treating control. There is a significant reduction of bacterial survival in the lungs of ETZ-treating mice compare to the mock-treating control. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | DL6390000 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.871 ml | 19.356 ml | 38.712 ml |
5 mM | 0.774 ml | 3.871 ml | 7.742 ml |
10 mM | 0.387 ml | 1.936 ml | 3.871 ml |
5 mM | 0.077 ml | 0.387 ml | 0.774 ml |
Use | In addition to its weak diuretic effect, ethoxypheniazolamide is mainly used for the treatment of glaucoma, cerebral edema, epileptic seizures and high altitude hypoxia leading to edema diseases and peptic ulcers. |
biological activity | Ethoxzolamide is an inhibitor of carbonic anhydrase with a Ki value of 1 nM. |
target | Ki: 1 nM (carbonic anhydrase) |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |